Cyclacel Reports On Sapacitabine Program: A Fly In The Ointment?
This article was originally published in The Pink Sheet Daily
Executive Summary
Cyclacel has made progress on its pivotal trial of lead candidate sapacitabine in AML. But there are questions about its potency as a monotherapy based on an under-reported European trial in which the sapacitabine arm was stopped for futility.